Designed for 23 genes explicitly recommended in the NCCN Guidelines that are relevant to the treatment of non-small cell lung cancer (NSCLC), this product includes the full exonic regions of these 23 genes, as well as hotspot fusion regions related to BRAF, ALK, RET, ROS1, MET Exon 14 skipping mutation, etc. It enables one-time detection of variation types such as mutations, fusions, copy number variations, and insertions/deletions, providing reference for clinical treatment decisions.
| Technical Platform | TargetSeq® Hybridization Capture Sequencing |
| Coverage Size | 170.1 kb |
| Reference Database | RefSeq |
| Reference Genome | GRCh37 (hg19) |
| Coverage | The full exonic regions of 23 NSCLC-related genes as well as the intronic regions related to hotspot fusions |
| Storage | -20℃±5℃ |
| Sequence Platform | Illumina / MGI |
| Recommend Sequencing Read Length | PE150 |
| Recommend Sequencing Data | 1Gb/1000× |
| Applications | Targeted therapy and immunotherapy guidance |
Comprehensively covers the CDS regions and intron regions of genes related to non-small cell lung cancer (NSCLC) for the detection of multiple variant types.
Efficiently captures target regions, reduces costs, and enables sensitive detection.
Leveraging iGeneTech® TargetSeq® probe hybridization capture sequencing technology, delivering stable and excellent performance.
Offers customizable and semi-customizable services (e.g., probe densification, expanding target regions) based on client needs, meeting personalized requirements.
Capture performance testing
Figure 1. Capture performance test of gDNA reference standards.
Note: Tested with gDNA reference standards. Libraries were constructed using the IGT® Fast Library Prep Kit v2.0, coupled with the TargetSeq One® Hyb & Wash Kit v3.0 hybridization and washing system, and sequenced on the Illumina NovaSeq 6000 with PE150 (paired-end 150).
| Gene | Variant | Expected allelic frequency | Reported allelic frequency |
EGFR | L858R | 1.0% | 1.7% |
KRAS | A146T | 1.0% | 0.7% |
NRAS | Q61K | 1.0% | 0.9% |
EGFR | T790M | 2.0% | 2.3% |
EGFR | ΔE746_A750 | 2.0% | 1.1% |
KRAS | G12D | 2.0% | 1.3% |
EGFR | V769_D770insASV | 3.0% | 1.4% |
EGFR | G719S | 4.0% | 4.3% |
KRAS | G13D | 4.0% | 3.3% |
EML4-ALK | Fusion | 5.0% | 2.4% |
CD74-ROS1 | Fusion | 6.0% | 2.9% |
BRAF | V600E | 7.0% | 6.3% |
PIK3CA | H1047R | 7.0% | 4.7% |
Note: Comparative analysis results of mutation site detection in positive reference standards. Libraries were constructed using gDNA reference standards (Jingliang, cat. GW-OPSM003) with an input amount of 50 ng, sequenced on the Illumina NovaSeq 6000 with PE150. When the depth after deduplication was ~1,000× (1 Gb raw bases), all positive mutation sites were detected, which is consistent with the expected results.
Gene | Variant | Expected allelic frequency | Reported allelic frequency |
NRAS | Q61K | 0.5% | 0.6% |
NRAS | A59T | 0.5% | 0.8% |
PIK3CA | E545K | 0.5% | 0.7% |
EGFR | ΔE746 - A750 | 0.5% | 0.6% |
EGFR | V769 - D770insASV | 0.5% | 0.6% |
EGFR | T790M | 0.5% | 0.6% |
EGFR | L858R | 0.5% | 0.6% |
KRAS | G12D | 0.5% | 0.8% |
Note: Comparative analysis results of mutation site detection in positive reference standards. Libraries were constructed with an input amount of 10 ng using cfDNA reference standards (Horizon, cat. HD780), sequenced on the Illumina NovaSeq 6000 with PE150. When the depth after deduplication was ~10,000× (4 Gb raw bases), all positive mutation sites were detected, which is consistent with the expected results.
| Product Name | Set | Cat. No |
| TargetSeq® NSCLC Panel V2 | 4 rxn | PH2000160 |
| 24 rxn | PH2000165 | |
| 96 rxn | PH2000162 |